Table SI. Adverse events leading to treatment discontinuation in 549 AD patients

		Biologics		*JAK inhibitors*		
	Total n = 759	**Dupilumab n = 492**	**Tralokinumab n = 51**	**Abrocitinib n = 43**	**Baricitinib n = 62**	**Upadacitinib n = 111**
Total number of AEs	174	132	7	8	12	15
Number of patients	85	83	6	7	11	12
Total number of treatment courses discontinued AEs	119	83	6	7	11	12
AEs:						
Acne, n (%)	2 (1.1)	0	0	0	0	2 (13.3)
Upper respiratory tract infection, n (%)	5 (2.9)	1 (0.8)	0	1 (12.5)	0	3 (20.0)
Gastrointestinal symptoms, n (%)	1 (0.6)	1 (0.8)	0	0	0	0
Head and neck dermatitis, n (%)	20 (11.5)	20 (15.2)	0	0	0	0
Weight gain, n (%)	2 (1.1)	0	0	0	1 (8.3)	1 (6.7)
Joint complaints, n (%)	12 (6.9)	10 (7.6)	1 (14.3)	0	1 (8.3)	0
Headache, n (%)	3 (1.7)	1 (0.8)	0	0	0	2 (13.3)
Herpes simplex, n (%)	5 (2.9)	2 (1.5)	0	0	3 (25.0)	0
Herpes zoster, n (%)	0	0	0	0	0	0
Liver dysfunction, n (%)	3 (1.7)	0	0	0	2 (16.7)	1 (6.7)
Malaise, n (%)	5 (2.9)	2 (1.5)	0	1 (12.5)	1 (8.3)	1 (6.7)
Myalgia, n (%)	1 (0.6)	0	0	1 (12.5)	0	0
Conjunctivitis, n (%)	76 (43.7)	71 (53.8)	5 (71.4)	0	0	0
Other, n (%)	39 (22.4)	24 (18.2)	1 (14.3)	5 (62.5)	4 (33.3)	5 (33.3)

Abbreviations: n:number of treatment courses; AE: adverse event